We use cookies to ensure that we give you the best experience on our website Learn more

Feb 4, 2019

12th International Conference on Advanced Technologies & Treatments for Diabetes

A RETROSPECTIVE CASE STUDY OF 12 WEEKS TO ASSESS GLYCEMIC AND NON-GLYCEMIC CHANGES WITH SGLT2I FROM DATA BASE OF 6 TYPE 2 DIABETIC PATIENTS

sodium glucose cotransporter 2 inhibitor

packed cell volume change

type 2 diabetes

waist circumference change

homa ir change

Abstract

Abstract

thumbnail

Keywords

sodium glucose cotransporter 2 inhibitor

packed cell volume change

type 2 diabetes

waist circumference change

homa ir change

Abstract

Introduction: Sodium-glucose transporter-2 (SGLT-2) inhibitors are newer agents with the advantage of weight loss. We have used SGLT-2 inhibitors –dapagliflozin, or, empagliflozin on T2D patients inadequately controlled on existing therapy and analyzed the results on glycemic and other non-glycemic parameters. Methods: We have clinic data of 6 patients collected after taking their written consent. Patients received treatment with SGLT2Is as per routine standard of care. The patients’ physical parameters (weight, waist circumference), C-reactive protein (CRP), packed cell volume (PCV), Hemoglobin (Hb), HOMA-Insulin resistance (HOMA IR) and HbA1c were taken from baseline clinic's data and their clinic data after 12 weeks of treatment. Results: After a mean study duration of 12 weeks, there was significant reduction in weight from 73 ± 2.48 kg (mean ± SEM) to 67.83 ± 2.32 kg ( reduction of 5.17 ± 2.14;p=0.003) along with significant increase in the packed cell volume (PCV) from 36.17 ± 2.05 (mean ± SEM) to 39.07 ± 1.81 (increase of 2.90 ± 2.07%; p=0.027). The waist circumference also reduced from 106.96 ± 7.96 to 102.33 ± 5.98. The hemoglobin also increased significantly from 11.85 ± 0.6 to 12.77 ± 0.681. Other parameters such as waist circumference, CRP, HOMA-IR, HbA1c remained unchanged (Table 1). Conclusion: There seems to be a persistence of non-glycemic index changes even without the change in HbA1c with the use of SGLT2Is. The changes in PCV and Hemoglobin throw a faint light on the chance of change of erythropoietin level with SGLT2I use in diabetics (as seen in other studies).

Discover over 20,000 new abstracts, posters and presentations from leading academic conferences every month. Stay on top of the latest findings, methodologies and discussions happening in your research field around the world.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.